 |
인쇄하기
취소
|
Ilyang, Daewoong sign deal to sell Supect
Ilyang Pharmaceutical Co. said Friday it established a strategic partnership with Daewoong Pharmaceutical Co. to sell Supect, a newly-developed drug for myelogenous leukemia by Ilyang, in Korea.
Under the deal, Ilyang will devote itself to carry out Phase 3 clinical trial of Supect, while Daewoong will be in charge of selling Supect using its extensive domestic distribution network.
Supec...
Under the deal, Ilyang will devote itself to carry out Phase 3 clinical trial of Supect, while Daewoong will be in charge of selling Supect using its extensive domestic distribution network.
Supec...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.